PARIS, France: A five-year-old girl with a rare neurodegenerative disease died in the US while taking part in a gene therapy trial run by French biotechnology company Lysogene, the firm said on Thursday.
The little girl was suffering from Sanfilippo syndrome or mucopolysaccharidosis type III, a rare genetic disease that alters brain development after birth and leads to premature death. In a statement Lysogene, a company developing gene therapy for central nervous system diseases in children, said "the immediate cause of death is currently unknown" and that there was as yet "no evidence that the event is linked to the study drug administration".
It said it was "profoundly saddened by the passing of this child" and was collecting "additional information" about the circumstances. The share price of the company dropped 19 percent to 2.05 euros in morning trading in Paris.
The girl was one of 19 people being treated in the trial conducted at eight hospitals in Europe and the United States. She died at home several months after receiving the therapy, consisting of a single injection, at one of four treatment sites in the US, Lysogene told AFP. In its statement the company said it was following the remaining 18 patients closely and remained "committed to the LYS-SAF302 development program".
Liberal Justice Elena Kagan on Sept. 13, 2016. — Slate website WASHINGTON: U.S. Supreme Court justices, wading back...
A representational image of inmates behind jail bars. — Unsplash/FileMOSCOW: A Russian court on Wednesday ordered...
Sudanese soldiers guard the surrounding area of the UNMIS compound in El-Fasher, the administrative capital of North...
US quietly shipped ATACMS missiles to Ukraine. — Report news agencyWASHINGTON: The United States in recent weeks...
US President Joe Biden during his address in California. — AFP FileWASHINGTON: President Joe Biden signed a...
The World Meteorological Organisation flag. — AFP FileGENEVA: Global temperatures hit record highs last year, and...